Casey Elizabeth Wing

Casey Elizabeth Wing

Auto-generated profile, based on publicly available information

Casey Elizabeth Wing

Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2022 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
CWCasey E. Wing
Casey E. Wing
HFHo Yee Joyce Fung
Ho Yee Joyce Fung
YCYuh Min Chook
Yuh Min Chook

31 October 2017 in Analytical Chemistry
Verified
Journal Article
Closed access
DPDaniel A. Plymire
Daniel A. Plymire
CWCasey E. Wing
Casey E. Wing
DRDana E. Robinson
Dana E. Robinson
SPSteven M. Patrie
Steven M. Patrie

21 November 2025 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
CWCasey E. Wing
Casey E. Wing
HFHo Yee Joyce Fung
Ho Yee Joyce Fung
BKBert Kwanten
Bert Kwanten
TCTolga Cagatay
Tolga Cagatay
ANAshley B. Niesman
Ashley B. Niesman
YCYuh Min Chook
Yuh Min Chook

16 July 2018 in Microbial Biotechnology
Verified
Journal Article
Open access
PDF file
CKChristine L. Kirkpatrick
Christine L. Kirkpatrick
NPNicole C. Parsley
Nicole C. Parsley
TBTessa E. Bartges
Tessa E. Bartges
CWCasey E. Wing
Casey E. Wing
SKSushma Kommineni
Sushma Kommineni
LHLeslie Hicks
Leslie Hicks
Summary: As current methods for antibiotic drug discovery are being outpaced by the rise of antimicrobial resistance, new methods and innovative technologies are necessary to replenish our dwindling arsenal of antimicrobial agents. To this end, we developed the Pep SAVI ‐ MS pipeline to expedite the search for natural product bioactive peptides. Herein we demonstrate expansion of Pep SAVI ‐ MS for the discovery of bacterial‐sourced bioactive peptides through identification of the bacteriocin Bac‐21 from Enterococcus faecalis pPD 1. Minor pipeline modifications including implementation of bacteria‐infused agar diffusion assays and optional digestion of peptide libraries highlight the versatility and wide adaptability of the Pep SAVI ‐ MS pipeline. Additionally, we have experimentally validated the primary protein sequence of the active, mature Bac‐21 peptide for the first time and have confirmed its identity with respect to primary sequence and post‐translational processing. Successful application of Pep SAVI ‐ MS to bacterial secretomes as demonstrated herein establishes proof‐of‐principle for use in novel microbial bioactive peptide discovery.

12 March 2026 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
CWCasey E. Wing
Casey E. Wing
YCYuh Min Chook
Yuh Min Chook

11 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CWCasey Elizabeth Wing
Casey Elizabeth Wing
HFHo Yee Joyce Fung
Ho Yee Joyce Fung
BKBert Kwanten
Bert Kwanten
TCTolga Cagatay
Tolga Cagatay
ANAshley B. Niesman
Ashley B. Niesman
YCYuh Min Chook
Yuh Min Chook
The nuclear export receptor exportin 1 (XPO1/CRM1) is often overexpressed in cancer cells, leading to the mislocalization of numerous cancer-related protein cargoes 1,2 . Selinexor, a covalent XPO1 inhibitor, and other Selective Inhibitor of Nuclear Export (SINEs) restore proper nuclear localization by blocking XPO1-cargo binding 2-7 . SINEs also induce XPO1 degradation via the Cullin-RING E3 ubiquitin ligase (CRL) substrate receptor ASB8 7 . Here we elucidate the mechanism underlying the high-affinity engagement of CRL5 ASB8 with SINE-conjugated XPO1. Cryogenic electron microscopy (cryoEM) structures reveal that ASB8 binds to a cryptic site on XPO1, which becomes accessible only upon SINE conjugation. While molecular glue degraders typically interact with both CRL and the substrate 8-10 , SINEs bind to XPO1 without requiring interaction with ASB8 for efficient XPO1 degradation. Instead, an allosteric mechanism facilitates high affinity XPO1-ASB8 interaction, leading to XPO1 ubiquitination and degradation. ASB8-mediated degradation is also observed upon treatment of the endogenous itaconate derivate 4-octyl itaconate, which suggests a native mechanism that is inadvertently exploited by synthesized XPO1 inhibitors. This allosteric XPO1 degradation mechanism of SINE compounds expands the known modes of targeted protein degradation beyond the well-characterized molecular glue degraders and proteolysis targeting chimeras of CRL4.